Consistent with enriched immune receptor expression in C-GBM tumors (see Figure 4) and immune abundance correlating with outcome (see Supplemental Figure 9), a 2-fold increase in PD-1 expression in CD4+ T cells (mmRAPID cluster 9) (Supplemental Figure 11B) and CD8+ T cells (mmRAPID cluster 25) (Supplemental Figure 11C) correlated with 2-fold worse survival (215 days vs. 441 days and 240 days vs. 570 days, respectively). This evidence concerns the gene CD4 and glioblastoma.